The Overwhelming Argument for Rescheduling Psilocybin to Schedule 2 in the Misuse of Drugs Regulations 2001.
Josh Normanton and Rob Jappie of Ince have co-written an article on the arguments for rescheduling psilocybin to Schedule 2 in the Misuse of Drugs Regulations 2001 to facilitate medical research into depressive illnesses.
In the article, they review the effect of current legal restrictions and explore evidence-based policy arguments for rescheduling. They also examine the compelling commercial case for rescheduling. The article has been published by the think tank Volteface which focuses on evidence-based drugs policy and reform.
The article is available here: